ABT263, also known as Navitoclax, is an orally active anti-cancer drug, that disrupts BCL2/BCL-XL interactions [18] and has been evaluated in several clinical trials of chronic lymphocytic leukemia, non-small cell lung cancer, ovarian cancer, and some other solid tumors [35,36]. The gene discussed is BCL2L1; the disease is non-small cell lung carcinoma.